Evidence map›Paper›PMID 26588892›Full record

ArticleInfluenza and other respiratory viruses2016

Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand.

Wanitchaya Kittikraisak, Malinee Chittaganpitch, Christopher J Gregory, Yongjua Laosiritaworn, Thanawadee Thantithaveewat, Fatimah S Dawood, Kim A Lindblade

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023
    Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Wanitchaya KittikraisakInfluenza Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Malinee ChittaganpitchNational Institute of Health, Ministry of Public Health, Nonthaburi, Thailand.
Christopher J GregoryInternational Emerging Infections Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Yongjua LaosiritawornBureau of Epidemiology, Ministry of Public Health, Nonthaburi, Thailand.
Thanawadee ThantithaveewatBureau of General Communicable Diseases, Ministry of Public Health, Nonthaburi, Thailand.
Fatimah S DawoodInfluenza Division, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Kim A LindbladeInfluenza Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Ministry of Public Health · THCenters for Disease Control and Prevention · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEach year, an influenza B strain representing only one influenza B lineage is included in the trivalent inactivated influenza vaccine (IIV3); a mismatch between the selected lineage and circulating viruses can result in suboptimal vaccine effectiveness. We modeled the added potential public health impact of a quadrivalent inactivated influenza vaccine (IIV4) that includes strains from both influenza B lineages compared to IIV3 on influenza-associated morbidity and mortality in Thailand.

methodsUsing data on the incidence of influenza-associated hospitalizations and deaths, vaccine effectiveness, and vaccine coverage from the 2007-2012 influenza seasons in Thailand, we estimated rates of influenza-associated outcomes that might be averted using IIV4 instead of IIV3. We then applied these rates to national population estimates to calculate averted illnesses, hospitalizations, and deaths for each season. We assumed that the influenza B lineage included in IIV3 would provide a relative vaccine effectiveness of 75% against the other B lineage.

resultsCompared to use of IIV3, use of IIV4 might have led to an additional reduction ranging from 0·4 to 14·3 influenza-associated illnesses per 100 000 population/year, <0·1 to 0·5 hospitalizations per 100 000/year, and <0·1 to 0·4 deaths per 1000/year. Based on extrapolation to national population estimates, replacement of IIV3 with IIV4 might have averted an additional 267-9784 influenza-associated illnesses, 9-320 hospitalizations, and 0-3 deaths.

conclusionCompared to use of IIV3, IIV4 has the potential to further reduce the burden of influenza-associated morbidity and mortality in Thailand.

Indexed as

Influenza VaccinesPublic HealthAntibodies, ViralCost of IllnessHospitalizationHumansInfluenza B virusInfluenza, HumanModels, StatisticalSeasonsThailandVaccines, InactivatedAntibodies, ViralInfluenza VaccinesVaccines, InactivatedInactivated influenza vaccinequadrivalentThailandtrivalent

Identifiers

PMID26588892
PMCPMC4814859
OpenAlexW2176028903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.